Immunocore

September 04, 2018

Zelluna joins the adoptive cell therapy chase

As the tiny Norwegian biotech gears up to put its first asset into the clinic, investors could use an ongoing trial to handicap its chances of success.

August 20, 2018

Amid Immunocore’s C-suite bloodletting Glaxo provides solace

Immunocore has recently been beset with multiple senior executive departures, but has managed to press on into phase I with a Glaxo-partnered asset.

July 16, 2018

Why Immatics could soon become the next listed cell therapy player

Immunocore and Adaptimmune could shortly have a publicly listed rival.

October 11, 2017

World Lung and SITC – two more doses of oncology

August 31, 2017

Corporate venture firms – dedicated followers of fashion?

Eagerly pursuing all the latest fads and trends.

October 13, 2016

Adaptimmune puts fludarabine back on the agenda

September 02, 2016

Snippet roundup: Tecentriq gets lung cancer win, Enbrel biosimilar patent dance intensifies

April 14, 2016

Interview – UK cell therapy minnow squares up to Juno

January 19, 2016

As venture capital flows freely, Europe's haves and have nots emerge

January 18, 2016

Biotechs raise record venture capital haul in 2015

October 14, 2015

Venture treasure bath for oncology, pennies for others

Load More